Literature DB >> 16007529

Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.

Carlos A DiazGranados1, Shanta M Zimmer, Mitchel Klein, John A Jernigan.   

Abstract

BACKGROUND: Whether vancomycin resistance is independently associated with mortality among patients with enterococcal bloodstream infection (BSI) is controversial. To address this issue, we performed a systematic literature review with meta-analysis.
METHODS: Data sources were studies identified using the MEDLINE database (for articles from 1988 through March 2003), the Cochrane Library (for articles published up to March 2003), and bibliographies of identified articles. Inclusion criteria were that the study assessed mortality after enterococcal BSI, compared mortality after vancomycin-resistant enterococci (VRE) BSI with that after vancomycin-susceptible enterococci (VSE) BSI, and adjusted for severity of illness. Study exclusion criteria were as follows: no report of the adjusted measure of effect (adjusted odds ratio [OR], adjusted hazard ratio, or adjusted relative risk) of vancomycin resistance on mortality available and/or its adjusted 95% confidence interval (95% CI). Data in the tables, figures, or text were independently extracted by 2 of the authors. Individual weights were calculated using the 95% CI of the adjusted measures of effect performing both fixed-effect and random-effects models.
RESULTS: Nine studies were eligible (11 studies met the inclusion criteria, and 2 were excluded), with a total of 1614 enterococcal BSI episodes (683 VRE episodes and 931 VSE episodes). Patients with bacteremia caused by VRE were more likely to die than were those with VSE bacteremia (summary OR, 2.52; 95% CI, 1.9-3.4).
CONCLUSIONS: Vancomycin resistance is independently associated with increased mortality among patients with enterococcal bloodstream infection.

Entities:  

Mesh:

Year:  2005        PMID: 16007529     DOI: 10.1086/430909

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  123 in total

1.  Lysozyme activates Enterococcus faecium to induce necrotic cell death in macrophages.

Authors:  Sabine Gröbner; Evelyn Fritz; Friederike Schoch; Martin Schaller; Alexander C Berger; Michael Bitzer; Ingo B Autenrieth
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

2.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

3.  Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.

Authors:  J A McKinnell; M Patel; R M Shirley; D F Kunz; S A Moser; J W Baddley
Journal:  Epidemiol Infect       Date:  2010-11-15       Impact factor: 2.451

4.  Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria.

Authors:  H N Khair; P VanTassell; J P Henderson; D K Warren; J Marschall
Journal:  J Hosp Infect       Date:  2013-08-30       Impact factor: 3.926

5.  Vancomycin-resistant enterococci colonization in patients with hematological malignancies: screening and its cost-effectiveness.

Authors:  Habip Gedik; Funda Şimşek; Arzu Kantürk; Taner Yıldırmak; Deniz Arıca; Demet Aydın; Osman Yokuş; Naciye Demirel
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

6.  Moving CLABSI prevention beyond the intensive care unit: risk factors in pediatric oncology patients.

Authors:  Matthew Kelly; Margaret Conway; Kathleen Wirth; Gail Potter-Bynoe; Amy L Billett; Thomas J Sandora
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09-20       Impact factor: 3.254

7.  [Prevention and control of the spread of vancomycin-resistant enterococci: results of a workshop held by the German Society for Hygiene and Microbiology].

Authors:  R-P Vonberg; I F Chaberny; A Kola; F Mattner; S Borgmann; M Dettenkofer; D Jonas; A-M Fahr; I Klare; G Werner; K Weist; C Wendt; P Gastmeier
Journal:  Anaesthesist       Date:  2007-02       Impact factor: 1.041

8.  Intensified strategies to control vancomycin-resistant enterococci in immunocompromised patients.

Authors:  M Schmidt-Hieber; I W Blau; S Schwartz; L Uharek; K Weist; T Eckmanns; D Jonas; H Rüden; E Thiel; C Brandt
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

9.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

10.  Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort.

Authors:  Anne M Butler; Margaret A Olsen; Liana R Merz; Rebecca M Guth; Keith F Woeltje; Bernard C Camins; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-01       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.